Cresco Labs CEO calls rescheduling of cannabis historic as it shifts from Schedule I to III under Controlled Substances Act.
Cresco Labs Inc., a leading cannabis company (CSE: CL) (OTCQX: CRLBF) (FSE: 6CQ), released a statement by CEO Charlie Bachtell commenting on President Trump's move to reschedule cannabis from Schedule I to Schedule III under the Controlled Substances Act. Bachtell referred to this decision as a significant milestone in the U.S. cannabis industry's history. The reclassification is expected to have a substantial impact on the cultural perception and legal status of cannabis.
Source: Unusual Whales The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments